degrader antibody conjugates

ocean wave curl
Biotech

Nurix gets BTK degrader back on track after FDA lifts hold

Nurix is hoping to surf a wave of interest in its BTK degraders now that the FDA has lifted a hold on a phase 1 trial of a B-cell malignancy drug.
James Waldron Mar 11, 2024 9:25am
Alphabet letters spelling

Are DACs the new ADCs? Seagen pays Nurix $60M to find out

Sep 7, 2023 10:35am